Efficacy of triple therapy for Helicobacter pylori infection using amoxicillin and clarithromycin and TAK-438 (vonoprazan) which is a novel potassium-competitive acid blocker to the patients treated unsuccessfully with PPI, amoxicillin and clarithromycin. - Efficacy of the treatment with TAK-438 (vonoprazan)/AC regimen for Helicobacter pylori infection to the patients treated unsuccessfully with PPI/AC regimen.

Finally, the eradication rate of H. pylori was 70.2% with a second-line regimen of TAK-438AC in patients for whom the firrst-line treatment with RAC failed. Our study shows promising results of H. pylori eradication with TAK-438-based triple therapy after proton pump inhibitor-based triple therapy failure, based on faster onset of increase in intragastric pH by TAK-438 (vonoprazan). Aliment Pharmacol Ther 2016; 43: 166